Uploaded September 2026 | Updated November 2026, 5 days ago
Foreign corporations are aggressively licensing Chinese biotech to bring novel, "first-in-class" drugs to global markets. This massive pipeline shift demonstrates that Chinese pharmaceutical talent is now producing assets that frequently match or outperform Western treatments in both efficacy and safety. Alice Han and James Kynge are joined by Ruby Wang on China Decode.
Foreign corporations are aggressively licensing Chinese biotech to bring novel, "first-in-class" drugs to global markets. This massive pipeline shift demonstrates that Chinese pharmaceutical talent is now producing assets that frequently match or outperform Western treatments in both efficacy and safety. Alice Han and James Kynge are joined by Ruby Wang on China Decode.










